Francisco Marty, MD, Dana-Farber Cancer Institute, discusses the initial results of the Phase III trial evaluating letermovir for CMV after bone marrow transplant.
Francisco Marty, MD
Advertisement
Articles by Francisco Marty, MD
Advertisement
Latest Updated Articles
Dr. Marty on Letermovir for CMV Prevention After Stem Cell TransplantFebruary 26th 2017
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
3
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
4
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
5